Axsome Therapeutics (NASDAQ:AXSM) Given New $186.00 Price Target at Royal Bank of Canada
Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its price objective decreased by investment analysts at Royal Bank of Canada from $193.00 to $186.00 in a research report issued on Thursday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Royal Bank of Canada’s target price points to a potential upside of 78.67% […]
Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its price objective decreased by investment analysts at Royal Bank of Canada from $193.00 to $186.00 in a research report issued on Thursday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Royal Bank of Canada’s target price points to a potential upside of 78.67% […]
